Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study
Publication
, Conference
Overman, MJ; Kopetz, S; Lonardi, S; McDermott, R; Leone, F; Leach, J; Lenz, HJ; Hendlisz, A; Morse, M; Garcia-Alfonso, P; Desai, J; Hill, A ...
Published in: Annals of Oncology
October 1, 2016
Duke Scholars
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi158
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Overman, M. J., Kopetz, S., Lonardi, S., McDermott, R., Leone, F., Leach, J., … André, T. (2016). Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study. In Annals of Oncology (Vol. 27, p. vi158). https://doi.org/10.1093/annonc/mdw370.27
Overman, M. J., S. Kopetz, S. Lonardi, R. McDermott, F. Leone, J. Leach, H. J. Lenz, et al. “Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study.” In Annals of Oncology, 27:vi158, 2016. https://doi.org/10.1093/annonc/mdw370.27.
Overman MJ, Kopetz S, Lonardi S, McDermott R, Leone F, Leach J, et al. Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study. In: Annals of Oncology. 2016. p. vi158.
Overman, M. J., et al. “Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study.” Annals of Oncology, vol. 27, 2016, p. vi158. Scopus, doi:10.1093/annonc/mdw370.27.
Overman MJ, Kopetz S, Lonardi S, McDermott R, Leone F, Leach J, Lenz HJ, Hendlisz A, Morse M, Garcia-Alfonso P, Desai J, Hill A, Moss RA, Goldberg MV, Lin CS, Tang H, André T. Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study. Annals of Oncology. 2016. p. vi158.
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi158
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis